@article{ATM22980,
author = {Francesco Passiglia and Silvia Novello},
title = {Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?},
journal = {Annals of Translational Medicine},
volume = {6},
number = {Suppl 2},
year = {2018},
keywords = {},
abstract = {In The New England Journal of Medicine, Horn and colleagues have recently published the results of the IMPower133, a randomized, placebo-controlled, phase III trial, combining the programmed-death ligand 1 (PD-L1) inhibitor atezolizumab or placebo with carboplatin and etoposide in treatment-naive patients with extensive-stage small-cell lung cancer (SCLC) (1).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/22980}
}